Lilly's next obesity drug just cut an average of 58 poundsprompting an all-out phase 3 blitz - FierceBiotech

[unable to retrieve full-text content]

1. Lilly's next obesity drug just cut an average of 58 pounds—prompting an all-out phase 3 blitz  FierceBiotech
2. A new weight-loss drug dubbed the 'triple G' could be stronger than Ozempic, Wegovy, and Mounjaro — and as powerful as bariatric surgery  Yahoo Life
3. Eli Lilly (LLY) Weight-Loss Shot Gives Company's Strongest Results in Trial  Bloomberg
4. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial  The Lancet
5. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial | NEJM  nejm.org
6. View Full Coverage on Google News

Lilly's next obesity drug just cut an average of 58 pounds—prompting an all-out phase 3 blitz - FierceBiotech
Read More